PLRX

Business Context and Reporting Period

Pliant Therapeutics, Inc. (PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. This Form 10-Q covers the quarterly period ended March 31, 2026. The company is currently prioritizing the development of its lead product candidate, PLN-101095, for solid tumors, following the discontinuation of its bexotegrast program in idiopathic pulmonary fibrosis (IPF) in mid-2025.

Key Financial Metrics

Note: The company reported no revenue for the period. Cash and cash equivalents were $22,190 and short-term investments were $148,702 as of March 31, 2026.

Material Changes vs. Prior Period

• Significant Reduction in Net Loss: Net loss decreased by approximately $36.1 million (64%) compared to Q1 2025, primarily driven by the discontinuation of the bexotegrast IPF program and workforce restructuring.
• Decrease in R&D Expenses: R&D expenses dropped by $29.9 million, largely due to the cessation of clinical trial costs for bexotegrast and reduced employee-related expenses following the 2025 restructuring.
• Decrease in G&A Expenses: General and administrative expenses decreased by $7.3 million, attributed to lower employee-related costs from reduced headcount.
• Debt Elimination: The company fully repaid its term loan with Oxford Finance LLC in October 2025; consequently, there was no interest expense in Q1 2026 compared to $0.8 million in Q1 2025.
• Investing Activities: Net cash used in investing activities was $4.1 million in Q1 2026, a reversal from the $69.1 million provided in Q1 2025, driven by purchases of short-term investments exceeding maturities.

Guidance, Outlook, and Risks

• Program Progress: The company announced the dosing of the first participant in the FORTIFY Phase 1b indication expansion trial for PLN-101095 in April 2026. Updated Phase 1 data presented at AACR 2026 showed anti-tumor activity in combination with pembrolizumab.
• Liquidity Outlook: Management believes existing capital resources ($172.4 million in cash and investments) are sufficient to fund operations for the next 12 months and beyond. An "at-the-market" (ATM) sales agreement with Leerink Partners LLC was entered into in March 2026 to raise up to $50.0 million, though no shares have been issued yet.
• Restructuring and Cost Management: The company continues to manage costs following a 45% workforce reduction in May 2025 and an additional restructuring in December 2025. It is evaluating options to reduce lease expenses, including subleasing or exiting its South San Francisco facility early.
• Key Risks:
  • Capital Needs: The company expects to continue incurring significant losses and will require substantial additional capital to complete clinical development.
  • Clinical Uncertainty: Success is highly dependent on PLN-101095; failure in clinical trials or safety issues could halt operations.
  • Third-Party Reliance: Reliance on third-party manufacturers, including single-source vendors in foreign jurisdictions like China, poses supply chain risks.
  • Regulatory and IP: Risks include failure to obtain regulatory approval, patent challenges, and changes in healthcare legislation affecting pricing and reimbursement.
• Subsequent Event: In April 2026, the Board approved an option repricing to $1.33 per share for outstanding options granted prior to March 1, 2025, subject to retention periods.

Investor Verification Checklist

• Verify the timeline and enrollment progress of the FORTIFY Phase 1b trial for PLN-101095.
• Monitor the utilization of the new $50.0 million ATM facility and any future equity dilution.
• Assess the impact of the April 2026 option repricing on future stock-based compensation expenses and employee retention.
• Review the status of lease negotiations for the South San Francisco headquarters to confirm potential cost savings.
• Track the company's cash burn rate against the stated 12-month liquidity runway.
• Confirm the supply chain stability of third-party manufacturers, particularly those located in China.